Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 Interest Coverage is 231.98 as of Jun. 2026, which is 261% above its 10-year median of 64.28. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 685 Drug Manufacturers companies, Korea United Pharm ranks better than 92.26% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Korea United Pharm's
Operating Income
for the
three
months ended in Jun. 2026 was ₩13,603 Mil. Korea United Pharm's Interest Expense for the
three
months ended in Jun. 2026 was ₩-59 Mil.
Korea United Pharm's interest coverage for the quarter that ended in Jun. 2026 was 231.98.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Korea United Pharm Inc has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Korea United Pharm's Interest Coverage or its related term are showing as below:
XKRX:033270'
s Interest Coverage Range Over the Past 10 Years
Min: 34.14 Med: 64.28 Max: 320.87
Current: 320.87
XKRX:033270's Interest Coverage is ranked better than 92.26% of 685
companies
in the Drug Manufacturers industry
Industry Median: 13.91
vs XKRX:033270: 320.87
Korea United Pharm (XKRX:033270) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Korea United Pharm Interest Coverage Related Terms
Korea United Pharm Interest Coverage Historical Data
* Premium members only.
The historical data trend for Korea United Pharm's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korea United Pharm (XKRX:033270) has a Interest Coverage of 231.98 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Korea United Pharm and its competitors. This is 261% above median its historical median of 64.28. Over the past decade, Korea United Pharm's Interest Coverage has ranged from 34.14 to 320.87. According to the industry distribution chart, Korea United Pharm ranks #53 out of 685 companies in the Drug Manufacturers industry, placing it in the top 7.7%.
Is Korea United Pharm's Interest Coverage too high?
Korea United Pharm's current Interest Coverage of 231.98 is 261% above median its 10-year median of 64.28. Over the past 10 years, this metric has ranged from a low of 34.14 to a high of 320.87. The Drug Manufacturers industry median Interest Coverage is 13.91. Korea United Pharm's value of 231.98 is 1567.7% above this industry median. Based on the distribution chart, Korea United Pharm ranks #53 out of 685 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #53 out of 685 companies for Interest Coverage. This places Korea United Pharm in the top 8% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 13.91. Korea United Pharm's value of 231.98 is 1567.7% above this benchmark. Historically, Korea United Pharm's own Interest Coverage has ranged from 34.14 to 320.87 over the past decade. While the company's 10-year median is 64.28 vs. the industry median of 13.91, Korea United Pharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.91, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current Interest Coverage of 231.98 is 1567.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current Interest Coverage is 231.98, which is 261% above median its own 10-year median of 64.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current Interest Coverage is 231.98, which is 261% above median its 10-year median of 64.28 and 1567.7% above the Drug Manufacturers industry median of 13.91. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current Interest Coverage is 231.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
Interest Coverage: 231.98 (261% above median its 10-year median of 64.28)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 1567.7% above the Drug Manufacturers median (#53 of 685)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
